12.5x Titer Boost Accelerates CAR-T Program To IND Filing

A therapeutic program facing stalled progress due to low and inconsistent viral titers overcame a major development barrier through a targeted plasmid‑engineering strategy. The team redesigned the lentiviral construct using a flexible, low‑recombination backbone and generated multiple new configurations optimized for packaging efficiency, expression, and safety. Through parallel evaluation of three novel designs against the original construct, the most productive architecture emerged quickly, enabling substantial gains during small‑scale testing.

After identifying the lead construct, process development advanced into stirred‑tank bioreactors with defined operating parameters to validate performance at scale. Subsequent GMP‑readiness activities included plasmid characterization, upstream optimization, and downstream purification verification to ensure long‑term manufacturing robustness. Results demonstrated a 12.5× increase in infectious titer, full analytical consistency across methods, and delivery of the materials and documentation required for regulatory submission. This upgrade in vector performance enabled uninterrupted clinical timelines and strengthened the foundation for future therapeutic advancement.